Clinical Trial: Calcimimetics in Hypophosphatemic Rickets

Study Status: Recruiting
Recruit Status: Unknown status
Study Type: Interventional

Official Title: Effect of Cinacalcet on the Long-Term Treatment of Familial Hypophosphatemic Rickets

Brief Summary: Currently, large oral doses of phosphate and 1,25(OH)2D (calcitriol) are the standard treatment of patients with familial hypophosphatemic rickets (XLH). While this therapy is effective in healing the rickets, it is often limited by development of complications due to the high dose of medications required to achieve cure. Among them are the development of calcifications in the kidneys and secondary hyperparathyroidism (HPT) which in some patients may cause complications like high blood calcium level, high blood pressure and damage to the kidney. A drug to treat secondary hyperparathyroidism was just developed. In a short term study we found that it might help the treatment of XLH, by allowing the use of lower doses of the both phosphate and calcitriol. In the present study we will learn if indeed the addition of this new medicine (Cinacalcet) to the long-term treatment will allow the use of lower doses of both phosphate and calcitriol and consequently lower the risk of complications.

Detailed Summary:
Sponsor: Children's Mercy Hospital Kansas City

Current Primary Outcome: doses of phosphate and calcitriol required to sustain goals of blood and urine chemistries [ Time Frame: 9 months ]

Original Primary Outcome: Same as current

Current Secondary Outcome:

Original Secondary Outcome:

Information By: Children's Mercy Hospital Kansas City

Dates:
Date Received: February 12, 2009
Date Started: February 2009
Date Completion:
Last Updated: February 13, 2009
Last Verified: February 2009